Cardiol Therapeutics Inc. (TSX: CRDL; OTCQX: CRTPF) is focused on producing the purest pharmaceutical CBD products and developing innovative therapies for heart disease, including acute myocarditis and other causes of heart failure. The Company's lead product, CardiolRx, is designed to be the safest and most consistent CBD formulation on the market. CardiolRx is pharmaceutically produced, cGMP certified, and does not contain any THC. The Company plans to commercialize CardiolRx during 2019 in the billion-dollar market for medicinal cannabinoids in Canada and is pursuing distribution opportunities in Europe and Latin America.
In heart failure, Cardiol is planning an international clinical study of CardiolRx in acute myocarditis, a condition caused by inflammation in heart tissue, which remains the most common cause of sudden cardiac death in people less than 35 years of age. The Company is also developing proprietary nanotechnology to uniquely deliver pharmaceutical CBD and other anti-inflammatory drugs directly to sites of inflammation in the heart that are associated with heart failure. Heart failure is the leading cause of death and hospitalization in North America with associated healthcare costs in the U.S. alone exceeding $30 billion. For further information about Cardiol Therapeutics, please visit www.cardiolrx.com.
- Science & Technology
- Therapeutic Targets
- Product Pipeline
- Investor Information
- Corporate Presentation
Latest Stock Info
Cardiol Therapeutics Announces Study Results Confirm the Cardioprotective Role of its Pharmaceutical Cannabidiol Formulation in a Model of Heart Failure
Cardiol Therapeutics Announces Filing of 2019 Year-End Financial Statements and MD
Cardiol Therapeutics Signs Supplier Agreement with Medical Cannabis by Shoppers, a Subsidiary of Shoppers Drug Mart Inc.
Cardiol Therapeutics Receives Health Canada Approval for Phase 1 Study of its Pharmaceutically Produced Cannabidiol (CBD) Formulation
Cardiol Therapeutics' Exclusive Manufacturing Partner Receives Three-Year Renewal and Amendment of its Cannabis Act License from Health Canada
Cardiol Therapeutics Appoints Michael J. Willner, Esq. as Business Advisor
Cardiol Therapeutics Appoints Former GW Pharmaceuticals Executive Colin Stott to Its Board of Directors
Cardiol Therapeutics Comments on the Descheduling of Purisys Cannabinoid Ingredients by U.S. Drug Enforcement Agency
Cardiol Therapeutics Announces Clinical Steering Committee for Phase 2 International Trial in Acute Myocarditis Using CardiolRx(TM) 100
Cardiol Therapeutics Announces Completion of Manufacturing Scale-up for Commercialization of CardiolRx(TM)100
Sorry, we weren't able to find any articles. Click here to return to our homepage.